CD274

Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial

Retrieved on: 
Thursday, March 30, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Bristol Myers Squibb, The New England Journal of Medicine, AACR, OS, NSCLC, RNA, Lung cancer, ELCC, PCR, BMY, CD8A, Patient, Checkmate, Risk, Cancer, Annual general meeting, Confidence interval, HR, EFS, Recurrence, Death, NYSE, Disease, Metastasis, Pharmaceutical industry, CD274, Nivolumab

While overall survival (OS) remained immature at this analysis, there was a continued encouraging trend in OS favoring neoadjuvant Opdivo with chemotherapy over chemotherapy alone (HR 0.62; 99.34% CI: 0.36 to 1.05).

Key Points: 
  • While overall survival (OS) remained immature at this analysis, there was a continued encouraging trend in OS favoring neoadjuvant Opdivo with chemotherapy over chemotherapy alone (HR 0.62; 99.34% CI: 0.36 to 1.05).
  • At three years, 78% of patients treated with neoadjuvant Opdivo and chemotherapy were alive, compared to 64% with chemotherapy alone.
  • These updated results will be featured in a proffered paper oral session at the European Lung Cancer Congress (ELCC) 2023 from March 29-April 1, 2023.
  • Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -816 clinical trial.

Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene

Retrieved on: 
Tuesday, April 12, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, LOH, Allele, Head, Cancer, U.S. Securities and Exchange Commission, HNSCC, College of American Pathologists, PSNL, Twitter, College, Genomics, DASH, Immunotherapy, MD, Nature Communications, Cervical cancer, PD-L1, Leadership, Machine learning, PCR, Patient, Form S-3, LinkedIn, Efficiency, SVP, NSCLC, Form, Nasdaq, Immune system, Method, CD274, HLA, Deletion, Clinical Laboratory Improvement Amendments, Medical imaging, Chief Justice of Hungary

Human leukocyte antigen loss of heterozygosity (HLA LOH) allows cancer cells to escape immune recognition by deleting HLA alleles, causing the suppressed presentation of tumor neoantigens.

Key Points: 
  • Human leukocyte antigen loss of heterozygosity (HLA LOH) allows cancer cells to escape immune recognition by deleting HLA alleles, causing the suppressed presentation of tumor neoantigens.
  • Despite its importance in immunotherapy response, few methods exist to detect HLA LOH, and their accuracy is not well understood.
  • Further, detecting HLA LOH accurately from sequencing data is of interest given the growing ubiquity of tumor molecular profiling.
  • The Personalis study details the development of DASH (Deletion of Allele-Specific HLAs), a novel machine learning-based algorithm to detect HLA LOH from paired tumor-normal sequencing data.

Informa Pharma Intelligence Launches 30th Edition Pharma R&D Annual Review

Retrieved on: 
Thursday, March 24, 2022
HCV, Degenerative disease, Plasma protein binding, D, Growth, Clinical trial, AAV, Nass, Drug pipeline, Novartis, Cancer, Lloyd, Intelligence, Rare, Roche, Pulse, Finger, Industry, Travel, Infection, Cell, COVID-19, Sofosbuvir, Sporting News Player of the Year Award, GLOBE, CD274, Company, NAS, PD-L1, Disease, Lilly, Gene, Fine chemical, Pharmaceutical industry, Medical device

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence , the global business intelligence provider for the biopharma industry, today announced the launch of its 30 th Edition Pharma R&D Annual Review .

Key Points: 
  • NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence , the global business intelligence provider for the biopharma industry, today announced the launch of its 30 th Edition Pharma R&D Annual Review .
  • Novartis has 64.8% of its pipeline targeting rare diseases, the highest of any top 10 pharma, with Lilly the lowest, at 28.2%.
  • [2004 Pharma R&D Report]
    Sovaldi (sofosbuvir), Gileads first-in-class small molecule for hepatitis-C, was in our list of novel NASs from 2013.
  • [2021 Pharma R&D Report]
    For more information, or to view the current and past reports, visit Informa Pharma Intelligence or contact [email protected] .

Cellworks Personalized Biosimulation Study Identifies Novel MDS Biomarkers and Immune Modulation Predictive of Therapy Response

Retrieved on: 
Tuesday, December 14, 2021
Data Management, Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Research, Software, Science, Clinical Trials, TRRAP, Personalized medicine, Clinical trial, MDS, Abstract, AZA, Disease, CBM, Drug resistance, Antigen, Biosimulation, HMA, Biomarker, Artificial intelligence, Myelodysplastic syndrome, CAV1, DAC, KDM4C, IFNA1, JAK2, MD, ASH, Society, Monosomy, Group, HIPK2, Research, Exposition, Agilent Technologies, DNA, VPA, HDAC, Software, Drug combination, Sequoia Capital, GSK3B, CD8, CTNNB1, Immunology, Azacitidine, UnitedHealth Group, Escape Room, Neoplasm, Patient, CD274, Medical device, Vaccine, Pharmaceutical industry, Decitabine

In the ASH Abstract 3690 study, the Cellworks Biosimulation Platform and CBM identified immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.

Key Points: 
  • In the ASH Abstract 3690 study, the Cellworks Biosimulation Platform and CBM identified immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.
  • The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients.
  • Cellworks Biosimulation Platform found that signaling pathway consequences related to CTNNB1 and c-MYC modulation predict response to DAC + VPA.
  • Biosimulation using the Cellworks Computational Omics Biology Model (CBM) identifies immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.